Belantamab mafodotin, lenalidomide, and dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin‐associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study-Reference-Cited by-同舟云学术

Belantamab mafodotin, lenalidomide, and dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin‐associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study

Published:2024-01-25 Issue:3 Volume:99 Page:502-504
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Gavriatopoulou Maria¹^ORCID,Ntanasis‐Stathopoulos Ioannis¹^ORCID,Malandrakis Panagiotis¹,Fotiou Despina¹,Migkou Magdalini¹,Theodorakakou Foteini¹,Spiliopoulou Vasiliki¹,Kanellias Nikolaos¹,Eleutherakis‐Papaiakovou Evangelos¹,Roussou Maria¹,Psarros Giorgos²,Kastritis Efstathios¹^ORCID,Dimopoulos Meletios A.¹^ORCID,Terpos Evangelos¹^ORCID

Affiliation:

1. Department of Clinical Therapeutics National and Kapodistrian University of Athens, School of Medicine Athens Greece

2. Health Data Specialists Dublin Ireland

Funder

GlaxoSmithKline

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27219

Reference6 articles.

1. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

2. Prevalence of Ocular Comorbidities in Elderly Patients with Multiple Myeloma in the US: An Analysis of 100% Medicare Sample Data during 2007-2020

3. Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma

4. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain

5. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma